Xifaxan (rifaximin) is a gut selective, non-systemic, virtually non-absorbed (less than 0.4%) oral antibiotic currently approved for the treatment of travelers’ diarrhea caused by noninvasive strains of E.coli
The company’s subsidiary Barr Laboratories has been given approval for clonazepam in 0.125mg, 0.25mg, 0.5mg, 1mg and 2mg measures. The company said it plans to launch the product
Enrollment in the study is expected to commence in the next few weeks with results expected around mid- year 2006. MX-3253 (celgosivir) is an alpha-glucosidase I inhibitor and
Pfizer is seeking FDA approval for Sutent as a treatment for malignant gastrointestinal stromal tumor and metastatic renal cell carcinoma among patients whose tumors do not respond to,
If the phase I trial data are promising, Corautus has the exclusive right to develop and commercialize VEGF-2 for the treatment of diabetic neuropathy, and will receive the
Patient enrollment, which has already begun, will not be completed until March 2006, with up to 10’000 patients being enrolled at over 500 centers. Results from the survey
The ‘Saskatchewan’ compounds appear to be highly potent chemopotentiators – drugs that enhance the activities of existing chemotherapeutic treatments. The compounds have also demonstrated activity in neurological and
Tests have shown that the company’s second attempt at finding an effective formulation that will combine the two drugs is still not as effective as taking both drugs
The survey found that 73% of Americans believe stem cell research could one day lead to new disease treatments and cures, and 70% support increasing federal funding for
OncoTac will provide Scott & White with quantities of anticancer drugs extracted from a group of substances called peptidotoxins. When developed using the company’s proprietary OncoMpact technology, these
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.